text_1: In patients with congenital heart defects, β-blockers significantly improve clinical heart failure outcomes.
text_2: The odds ratio for worsened outcome for patients in the combined carvedilol group vs the placebo group was 0.79 (95% CI, 0.36-1.59; P = .47).